Drug intelligence / Profile preview

NU7026

Development stage
Preclinical
Lead developer
Newcastle University
Modality
Small Molecules
Administration
Topical
01

Overview

NU7026 is a potent and selective small-molecule inhibitor of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). It functions by competitively inhibiting the ATP-binding site of DNA-PKcs, which is a critical component of the non-homologous end joining (NHEJ) pathway for repairing DNA double-strand breaks (DSBs). By blocking this repair mechanism, NU7026 acts as a potent radiosensitizer and chemosensitizer, enhancing the cytotoxic effects of ionizing radiation and various DNA-damaging agents such as topoisomerase II inhibitors (e.g., etoposide) and alkylating agents (e.g., melphalan). While NU7026 is extensively used as a research tool to investigate DNA damage response and repair biology, it has also been explored in preclinical models for various cancers, including prostate, lung, and ovarian cancers, as well as non-oncological conditions like hypoxic pulmonary hypertension and atherosclerosis.

Other names
2-(morpholin-4-yl)benzo[h]chromen-4-one2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one
02

Targets

ATM (Ataxia telangiectasia mutated protein)ATR (ATR serine/threonine kinase)DNA-PK (DNA-dependent protein kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on NU7026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NU7026.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call